Dublin, May 07, 2021 (GLOBE NEWSWIRE) -- The "Connected / Smart Drug Delivery Systems Market by Product Type, Therapeutic Area (Metabolic Disorders, Neurological Disorders, Respiratory Disorders and Others) and Key Geographical Regions: Industry Trends and Global Forecasts 2020-2030" report has been added to ResearchAndMarkets.com's offering.
The report features an extensive study of the current landscape and future outlook of the growing market for connected drug delivery devices that are either already commercialized or are under development.
One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on parameters, such as target consumer segments, likely adoption rates and expected pricing, we have provided an informed estimate on the likely evolution of the market in mid to long-term, for the period 2020-2030.
Our year-wise projections of the current and future opportunity have further been segmented on the basis of:
- Type of solution (connected drug delivery devices and add-on sensors)
- Type of product (connected inhalers, connected handheld injectors and connected wearable injectors)
- Therapeutic areas (metabolic disorders, neurological disorders, respiratory disorders, and others)
- Route of administration (injectable and inhalable)
- Key geographical regions (North America, Europe, Asia-Pacific, Latin America, MENA and rest of the world).
To account for the uncertainties associated with the development of these connected drug delivery devices and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market's evolution.
Amongst other elements, the report features:
- A detailed assessment of the current market landscape of more than 65 connected drug delivery devices based on a number of relevant parameters such as
- Type of device, namely connected inhalers, connected handheld injectors (connected pen injectors, connected autoinjectors and connected needle-free injectors) and connected wearable injectors (connected insulin pumps and connected patch pumps)
- Status of development (approved / launched or under development)
- Mode of drug delivery (injectable, inhalation and oral)
- Targeted therapeutic area (metabolic disorders, respiratory disorders, neurological disorders, hormonal disorders and others)
- Type of connectivity solution offered,
- Other key device specifications (audio / visual reminders, connectivity, companion mobile applications, companion web portal, data storage / cloud platform options, rechargeable batteries / battery backup and reminder / notifications / alerts).
Key Questions Answered
- Who are the leading developers of connected / smart drug delivery systems?
- What are the popular types of drug delivery devices that are currently being marketed / developed in this domain?
- What are the novel / advanced features that device developers are incorporating in their respective devices, to maintain a competitive edge in the market?
- What is the relative competitiveness of different connected solutions across several device segments?
- What kind of partnership models are commonly being adopted by stakeholders in this industry?
- What is the trend in capital investments in the connected drug delivery device market?
- What is the overall cost distribution across the value chain of connected drug delivery devices?
- What is the impact of COVID-19 outbreak on connected drug delivery devices market?
- What are the factors that are likely to influence the evolution of this market?
- How is the current and future market opportunity likely to be distributed across key market segments?
- What are the anticipated future trends related to connected drug delivery devices market?
COMPANY PROFILES
- Company Profiles
- BIOCORP
- Elcam Drug Delivery Devices (E3D)
- Novo Nordisk
- Merck
- Pneuma Respiratory
- H&T Presspart
- Nemera
Companies Mentioned
- 3E Bioventures Capital
- 3M
- 5AM Ventures
- A. Menarini Diagnostics
- Abbott
- Academic Pediatric Association
- Adherium
- Adocia
- Aerobit Health
- AgaMatrix
- Aguettant
- AIRBRIO
- Airnest
- Allegheny Health Network
- AMC Health
- Amiko
- Andaluz Health Service
- Anthem Blue Cross and Blue Shield
- Apellis Pharmaceuticals
- Aptar Pharma
- Aristotle University of Thessaloniki
- ARTORG Center
- Asante Solutions
- Asthma and Respiratory Foundation NZ
- AstraZeneca
- Australasian Medical & Scientific
- Bank of China Group Investment
- Barbara Davis Center
- Bayer
- Becton Dickinson
- Bigfoot Biomedical
- BioAdvance
- BIOCORP
- BioScience Managers
- Black Pearls
- Blackstone Life Sciences
- Blue Cross and Blue Shield
- Boehringer Ingelheim
- Robert Bosch Venture Capital
- Bosman Medical Devices
- Boston Children's Hospital
- Breed Reply
- Calgary Health Trust
- Cam Med
- Cambridge Consultants
- Cambridge University Hospitals
- Capital Royalty Partners II
- Centre Hospitalier de Luxembourg
- Chengdu Municipal Government
- Children's Hospital of Philadelphia
- Christchurch Clinical Studies Trust
- Chronicare
- Cincinnati Children's Hospital
- CincyTech
- Cintrifuse
- Cleveland Clinic
- Cognita Labs
- Cohero Health
- Common Sensing
- Companion Medical
- Connecticut Children's Medical Center
- Cormorant Asset Management
- Crux Product Design
- Debiotech
- Desert Oasis Healthcare
- Dexcom
- Diabeloop
- Diabnext
- DreaMed Diabetes
- E3D Elcam Drug Delivery Devices
- Eli Lilly
- EMD Serono
- Emory University
- Emperra
- Enable Injections
- EOFlow
- etectRx
- Eularis
- International Diabetes Federation
- Express Scripts
- Fenway Health
- Fidelity International
- FindAir
- Fitbit
- Flex Digital Health
- Gecko Health (acquired by Teva Pharmaceuticals)
- Genentech
- Gerresheimer
- Gilead Sciences
- GIS Strategic Ventures
- Glooko
- Gloria Pharmaceuticals
- GlucoRx
- GSK
- H&T Presspart
- Haisco Pharmaceutical
- Hamad Medical
- Harvard University
- Haselmeier
- Health Innovations
- Health2Sync
- HealthPartners Institute
- HealthPrize Technologies
- Heitkamp & Thumann Group
- HGE Health
- Hikma Ventures
- Hoffmann-La Roche
- HP Labs
- Huons
- IBM
- Idea Bridge
- ImagineCare
- Imperial College London
- Indiana University
- INKEF Capital
- Innovation Zed
- Institut de Recherches Cliniques de Montreal
- Insulclock
- Insulcoud S.L.
- Insulet
- International Clinical Trials Association
- International Diabetes Center at Park Nicollet
- Investitionsbank des Landes Brandenburg
- Invest-NL
- iSage Rx
- i-SENS
- iSense
- Ismanis Engineering
- Jaeb Center for Health Research
- Janus Henderson
- JDRF T1D Fund
- Joslin Diabetes Center
- Juvenile Diabetes Research Foundation
- K2 HealthVentures
- Kali Care
- Kap Code
- K-Bio Health
- Klue
- Kreos Capital
- LB Investment
- Leads Biolabs
- Legacy Health
- LEO Pharma
- Life Sciences Partners
- LINDAL Group
- Lupin
- Luz Saude
- The University of Manchester
- McKesson Ventures
- MedCrypt
- Medical International Research
- Medical Research Institute of New Zealand
- Medical University of Graz
- Medical University of South Carolina
- Medtronic
- Medtrum
- Merck KGaA
- MidMichigan Health
- Mode
- Molina Healthcare
- Monaghan Medical Corporation
- Morningside Venture Capital
- Mountain Diabetes and Endocrine Center
- Movi
- mySugr
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- National Institutes of Health
- National Library of Medicine (NLM)
- Navia Life Care
- Nemera
- Nemours
- New World Health
- New Zealand Medical & Scientific
- nGageIT Digital Health Solutions
- NHS Foundation Trust
- Noble International
- Nordic Infucare
- Northwestern University
- Norton Healthcare
- Novartis
- Novo Nordisk
- National Science Foundation
- Nutrino Health (acquired by Medtronic)
- Ohio Innovation Fund
- OMRON Healthcare
- One Drop
- One Funds Management
- Oregon Health and Science University
- ORI Healthcare Fund
- Orion
- Otsuka Pharmaceutical
- Owen Mumford
- Owsley Brown Charitable Foundation
- P5 Health Ventures
- Patients Know Best
- Pendiq
- Peppermint VenturePartners
- PercuSense
- PharmaSens
- Planet Innovation
- Pneuma Respiratory
- Portal Instruments
- ProCare
- Propeller Health
- Proteus Digital Health
- Quadrant Capital Advisors
- Qualcomm
- Qualicaps
- QuiO
- Quotient Sciences
- Rabin Medical Center
- Reciprocal Labs
- ResMed
- Respia
- Rimidi
- Roche
- Philips
- Rubin Medical
- Safeguard Scientifics
- Sagentia
- Samsung
- Sanner
- Sanofi
- Sansum Diabetes Research Institute
- Schneider Children's Medical Center
- Senseonics
- Sensile Medical
- Senvest Capital
- Sequoia Capital China
- SFC Fluidics
- SHL Medical
- Sidra Medicine
- Sirma Medical Systems
- Smartgateways
- Smile
- Sonceboz
- Sonmol
- SOOIL Development
- Sorrel Medical
- SQ Innovation
- SR One
- Stanford University
- Stevanato Group
- Summatix
- Sunrise Labs
- Swanhill Capital
- Syneos Health
- T1D Exchange
- Takeda Pharmaceutical
- Tandem Diabetes Care
- Teva Pharmaceuticals
- Texas Diabetes & Endocrinology
- The Leeds Teaching Hospitals
- Massachusetts Life Sciences Center (MLSC)
- Thea Group
- Theras
- Three Leaf Ventures
- Tidepool
- Timesulin
- Trade Capital Funding
- Trudell Medical
- TypeZero Technologies (acquired by Dexcom)
- UCB
- UnitedHealth
- Grenoble Alpes University Hospital
- University of Alabama
- University of Calgary
- University of California
- University of Cambridge
- University of Colorado
- University of Edinburgh
- University of Florida
- University of Ljubljana
- University of Minnesota
- University of Padova
- University of Pennsylvania
- University of Virginia
- Vatel Capital
- Vectura Group
- Verily
- ViCentra
- Visionnaire Ventures
- Vitalus Health
- Waterline Ventures
- Welkin Health
- West Pharmaceutical Services
- Xeris Pharmaceuticals
- Yale University
- Ypsomed
- Zaffre Investments
- Zealand Pharma
- Zhangjiang Venture Investment
For more information about this report visit https://www.researchandmarkets.com/r/ks6mg5